ATG5 also contributes to DOX resistance, and the upregulation of GBCDRlnc1 (gallbladder cancer drug resistance–associated lncRNA1) in DOX-resistant gallbladder cancer decreases phosphoglycerate kinase 1 (PGK1) degradation and upregulates ATG5 and ATG12 (208). Here, ATG5 is linked to gallbladder cancer.